



Think Differently About
the Way You Manage
Fluid Overload



CHF Solutions

CHF Solutions is focused on transforming the way fluid overloaded patients are treated for heart failure and related conditions by using the Aquadex FlexFlow system. Our objective is to improve the quality of life for patients with heart failure and related conditions. At CHF Solutions, we are committed to the relentless pursuit of identifying and developing innovative solutions to address the significant unmet clinical need with the goal of benefiting patients, medical practitioners, and hospital administrators.

Aquadex FlexFlow® System

The Aquadex FlexFlow Ultrafiltration (UF) System is designed to safely, effectively, and predictably remove excess fluid (primarily excess salt and water) from patients suffering from fluid overload who have failed diuretic therapy. With the Aquadex FlexFlow, medical practitioners can specify and control the amount of fluid to be extracted at a safe, predictable, and effective rate.

Supporting Clinical Evidence

Aquadex FlexFlow was studied in more heart failure patients than any other ultrafiltration system combined. Several trials including:

- The UNLOAD study showed that patients had 38% greater weight loss, 53% reduction in total number of re-hospitalizations for HF, 52% reduction in Emergency Department or clinic visits, and 63% total reduction in days re-hospitalized.
- SAFE, the preliminary safety and efficacy study, demonstrated fluid removal goals were achieved in 92% of treatments.
- RAPID-HF and UNLOAD studies also demonstrated clinical benefit of UF as compared to diuretics.
- JACC May 16, 2017 - when examining ultrafiltration for fluid overload in heart failure, adjustable UF rates vs. fixed rates may be associated with more effective decongestion and fewer heart failure events.
- The CARRESS trial, the only study to not allow UF treatment adjustments or customization, showed a rise in creatinine among renal patients on a fixed UF treatment strategy as compared to diuretics. Although, creatinine levels normalized at 7 days post treatment.

*Check
out the
latest article
on Ultrafiltration
featured in JACC
(May 16, 2017 issue)*

aquadex
FlexFlow

A Differential Mechanism of Action

The Aquadex FlexFlow[®] system can offer restoration of diuretic agent responsiveness, enables precise control of the rate and amount of sodium and fluid removal, and has been shown to have no clinically significant impact on electrolyte balance, blood pressure or heart rate.¹



Clinical and Economic Advantages

- Simple to use, highly automated, and provides precise control of rate and amount of fluid removed
- Extracts more sodium than diuretic therapy while sparing potassium and magnesium²
- Restores diuretic responsiveness³
- Sustained benefits of early and adjustable UF³
- Reduced number of rehospitalizations⁴
- Reduced unscheduled ER visits⁵
- Fewer rehospitalization days due to CV event⁴
- May be administered in Non-Intensive Care Units

Contact Us for More Information

1-855-786-2778

support@chf-solutions.com

Rx Only

Indication: The Aquadex FlexFlow[®] System is indicated for temporary (up to 8 hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy; and extended (longer than 8 hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. All treatments must be administered by a healthcare provider, under physician prescription, both of whom having received training in extracorporeal therapies.

¹Bart BA, et al. (RAPID) J Am Coll Cardiol. 2005 Dec 6; 46(11): 2043-2046.

²Ali SS, et al. Congest Heart Fail. 2009; 15(1):1-4.

³Costanzo MR, et al., J Am Coll Cardiol., 2017; 69: 2428-45.

⁴Costanzo, et al. (AVOID-HF) Am Heart J 2015;170: 471-82.

⁵Costanzo MR, et al. (UNLOAD) J Am Coll Cardiol. 2007 Feb 13; 49(6): 675-683.